Table 7 Improvement of length measurements in subjects receiving 500 mg bevonescein from the VSS

From: Intraoperative nerve-specific fluorescence visualization in head and neck surgery: a Phase 1 trial

 

0% Improvement

Up to 5% improvement

5–10% improvement

11–20% improvement

>20% improvement

Per nervea

(n = 54)

22% (n = 12/54)

18% (n = 10/54)

13% (n = 7/54)

18% (n = 10/54)

28% (n = 15/54)

Per subjectb

(n = 14)

0 %

14% (n = 2/14)

21% (n = 3/14)

7% (n = 1/14)

57% (n = 8/14)

  1. aPer nerve analysis assumes nerves are independent observations.
  2. bPer subject analysis uses the mean score of all nerves assessed per subject as the unit of analysis.
  3. VSS Visualization Scoring System.
  4. Note: the length measurement component of the VSS was evaluated from images of 14 subjects who received 500 mg of bevonescein in the following cohorts: dose-escalation (n = 3), dose-timing (n = 11). No statistical adjustments were made if the number of visualized nerves differed per patient.
Back to article page